Research programme: diabetes therapeutics - ProteoTechAlternative Names: islet amyloid polypeptide inhibitors - ProteoTech; Type-2 diabetes therapeutics - ProteoTech
Latest Information Update: 28 Aug 2014
At a glance
- Originator ProteoTech
- Class Small molecules
- Mechanism of Action Islet amyloid polypeptide inhibitors
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Type 2 diabetes mellitus
Most Recent Events
- 28 Aug 2014 Preclinical trials in Type-2 diabetes mellitus in USA (unspecified route)